<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32321526</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>22</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections.</ArticleTitle><Pagination><StartPage>58</StartPage><MedlinePgn>58</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">58</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-020-01328-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prophylactic vaccines are critical in preventing hand, foot, and mouth disease (HFMD) primarily caused by human enterovirus 71 (EV71) infection. Children aged less than 5&#x2009;years are especially susceptible to EV71 infections. In addition to the development of vaccines containing the inactivated virus, those containing virus-like particles (VLPs) with repeated antigens also constitute an effective preventive strategy for EV71 infections, with safety and productivity advantages. We previously developed a fusion protein composed with truncated peptides of the EV71 capsid protein, which assembled into spherical particles. This study aimed to assess the immunoprotective effects of this fusion protein as a vaccine candidate in a mouse model of EV71 infection.</AbstractText><AbstractText Label="METHODS">To evaluate the protective effect of fusion protein vaccine candidate, neonatal mice born by immunized female mice, as well as normal neonatal mice immunized twice were infected with EV71 virus. Whereafter, the survival rates, clinical scores and viral loads were measured.</AbstractText><AbstractText Label="RESULTS">The high dosage and booster immunization helped induce specific serum antibodies with high neutralization titers, which were transferred to neonatal mice, thereby facilitating effective resistance towards EV71 infection. An active immune response was also observed in neonatal mice which generated following immunization.</AbstractText><AbstractText Label="CONCLUSIONS">The present results suggest that this fusion protein is a suitable vaccine candidate in treating EV71 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiangning</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&amp;PUMC, Beijing, 100021, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&amp;PUMC, Beijing, 100021, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&amp;PUMC, Beijing, 100021, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yanfeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&amp;PUMC, Beijing, 100021, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yongdong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, People's Republic of China. ydliu@ipe.ac.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China. ydliu@ipe.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Chuan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, CAMS&amp;PUMC, Beijing, 100021, People's Republic of China. qinchuan@pumc.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014760">Viral Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014760" MajorTopicYN="N">Viral Fusion Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fusion protein</Keyword><Keyword MajorTopicYN="N">Human Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Mouse model</Keyword><Keyword MajorTopicYN="N">Vaccine candidate</Keyword></KeywordList><CoiStatement>The authors declare that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32321526</ArticleId><ArticleId IdType="pmc">PMC7178760</ArticleId><ArticleId IdType="doi">10.1186/s12985-020-01328-8</ArticleId><ArticleId IdType="pii">10.1186/s12985-020-01328-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortner B, Huang CW, Schmid D, Mutz I, et al. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol. 2009;81:317&#x2013;324. doi: 10.1002/jmv.21374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21374</ArticleId><ArticleId IdType="pubmed">19107980</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowlkes AL, Honarmand S, Glaser C, Yagi S, et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis. 2008;198:1685&#x2013;1691. doi: 10.1086/592988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/592988</ArticleId><ArticleId IdType="pubmed">18959496</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol. 2009;154:1139&#x2013;1142. doi: 10.1007/s00705-009-0413-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-009-0413-x</ArticleId><ArticleId IdType="pubmed">19506798</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Liu CC. Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti-Infect Ther. 2014;12:447&#x2013;456. doi: 10.1586/14787210.2014.895666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14787210.2014.895666</ArticleId><ArticleId IdType="pubmed">24579906</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the outbreak study group. Clin Infect Dis. 2000;31:678&#x2013;683. doi: 10.1086/314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus epidemic working group. N Engl J Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu H, Shimizu Y, Takeuchi Y, et al. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol. 1999;20:17&#x2013;23. doi: 10.1016/S0887-8994(98)00087-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0887-8994(98)00087-3</ArticleId><ArticleId IdType="pubmed">10029254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133:795&#x2013;798. doi: 10.1016/S0022-3476(98)70155-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(98)70155-6</ArticleId><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT. The current status of the disease caused by Enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13:890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, et al. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6:4&#x2013;14. doi: 10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zeng G, Chu K, et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum Vaccin Immunother. 2018;14:1517&#x2013;1523. doi: 10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829&#x2013;837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) Expert Rev Vaccines. 2016;15:599&#x2013;606. doi: 10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Meng FY, Mao Q, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother. 2014;10:1366&#x2013;1372. doi: 10.4161/hv.28397.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue L, Liu JN, Wang Q, et al. Purification and assembling a fused capsid protein as an enterovirus 71 vaccine candidate from inclusion bodies to pentamer-based nanoparticles. Biochem Eng J. 2017;117:139&#x2013;146. doi: 10.1016/j.bej.2016.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bej.2016.10.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed Z, Cardosa MJ. Status of research and development of vaccines for enterovirus 71. Vaccine. 2016;34:2967&#x2013;2970. doi: 10.1016/j.vaccine.2016.02.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.077</ArticleId><ArticleId IdType="pubmed">26973065</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305&#x2013;1312. doi: 10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lua LH, Connors NK, Sainsbury F, et al. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111:425&#x2013;440. doi: 10.1002/bit.25159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.25159</ArticleId><ArticleId IdType="pubmed">24347238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Ku Z, Zhang X, et al. Structure, immunogenicity, and protective mechanism of an engineered Enterovirus 71-like particle vaccine mimicking 80S empty capsid. J Virol. 2018;92:e01330&#x2013;e01317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5730765</ArticleId><ArticleId IdType="pubmed">29070691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58&#x2013;83. doi: 10.1016/j.vaccine.2012.10.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.083</ArticleId><ArticleId IdType="pmc">PMC7115575</ArticleId><ArticleId IdType="pubmed">23142589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Gao F, Mao Q, et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11:2406&#x2013;2413. doi: 10.1080/21645515.2015.1053675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1053675</ArticleId><ArticleId IdType="pmc">PMC4635907</ArticleId><ArticleId IdType="pubmed">26036916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855&#x2013;1862. doi: 10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia CS, Liu JN, Li WB, et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J. 2010;7:47. doi: 10.1186/1743-422X-7-47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-47</ArticleId><ArticleId IdType="pmc">PMC2839975</ArticleId><ArticleId IdType="pubmed">20170551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444&#x2013;7451. doi: 10.1016/j.vaccine.2010.08.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.080</ArticleId><ArticleId IdType="pubmed">20831911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol. 2008;82:7591&#x2013;7600. doi: 10.1128/JVI.00768-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00768-08</ArticleId><ArticleId IdType="pmc">PMC2493310</ArticleId><ArticleId IdType="pubmed">18508884</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809&#x2013;1814. doi: 10.1212/01.wnl.0000262031.18018.1a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000262031.18018.1a</ArticleId><ArticleId IdType="pmc">PMC2668699</ArticleId><ArticleId IdType="pubmed">17515542</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yang Y, Xu Y, et al. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J. 2011;8:483. doi: 10.1186/1743-422X-8-483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-483</ArticleId><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed LJMMH. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493&#x2013;497.</Citation></Reference><Reference><Citation>Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197:854&#x2013;857. doi: 10.1086/527326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/527326</ArticleId><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, et al. 2-year efficacy, immunogenicity, and safety of Vigoo Enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215:56&#x2013;63. doi: 10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Jiang S, Wang Y. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun. 2013;430:387&#x2013;393. doi: 10.1016/j.bbrc.2012.11.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.11.035</ArticleId><ArticleId IdType="pubmed">23159634</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo C, Yang J, Lei L, et al. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine. 2017;35:7322&#x2013;7330. doi: 10.1016/j.vaccine.2017.10.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.10.101</ArticleId><ArticleId IdType="pubmed">29129453</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88:5803&#x2013;5815. doi: 10.1128/JVI.00289-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00289-14</ArticleId><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81:9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W, Zeng G, Hu YM, et al. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. Expert Rev Vaccines. 2018;17:257&#x2013;262. doi: 10.1080/14760584.2018.1430572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1430572</ArticleId><ArticleId IdType="pubmed">29363365</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Sun B, Sun S, et al. Characterization of human enterovirus71 virus-like particles used for vaccine antigens. PLoS One. 2017;12:e0181182. doi: 10.1371/journal.pone.0181182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181182</ArticleId><ArticleId IdType="pmc">PMC5521781</ArticleId><ArticleId IdType="pubmed">28732070</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan P, Li X, Sun S, et al. Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease. Viruses. 2015;7:1558&#x2013;1577. doi: 10.3390/v7041558.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7041558</ArticleId><ArticleId IdType="pmc">PMC4411665</ArticleId><ArticleId IdType="pubmed">25826188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>